Department of Health Policy and Strategic Relations, American Society for Blood and Marrow Transplantation, Chicago, Illinois.
Duke University Margolis Center for Health Policy, Durham, North Carolina.
Biol Blood Marrow Transplant. 2018 Jan;24(1):4-12. doi: 10.1016/j.bbmt.2017.09.012. Epub 2017 Sep 28.
Patient-centered medical home models are fundamental to the advanced alternative payment models defined in the Medicare Access and Children's Health Insurance Plan Reauthorization Act (MACRA). The patient-centered medical home is a model of healthcare delivery supported by alternative payment mechanisms and designed to promote coordinated medical care that is simultaneously patient-centric and population-oriented. This transformative care model requires shifting reimbursement to include a per-patient payment intended to cover services not previously reimbursed such as disease management over time. Payment is linked to quality measures, including proportion of care delivered according to predefined pathways and demonstrated impact on outcomes. Some medical homes also include opportunities for shared savings by reducing overall costs of care. Recent proposals have suggested expanding the medical home model to specialized populations with complex needs because primary care teams may not have the facilities or the requisite expertise for their unique needs. An example of a successful care model that may provide valuable lessons for those creating specialty medical home models already exists in many hematopoietic cell transplantation (HCT) centers that deliver multidisciplinary, coordinated, and highly specialized care. The integration of care delivery in HCT centers has been driven by the specialty care their patients require and by the payment methodology preferred by the commercial payers, which has included bundling of both inpatient and outpatient care in the peritransplant interval. Commercial payers identify qualified HCT centers based on accreditation status and comparative performance, enabled in part by center-level comparative performance data available within a national outcomes database mandated by the Stem Cell Therapeutic and Research Act of 2005. Standardization across centers has been facilitated via voluntary accreditation implemented by Foundation for the Accreditation of Cell Therapy. Payers have built on these community-established programs and use public outcomes and program accreditation as standards necessary for inclusion in specialty care networks and contracts. Although HCT centers have not been described as medical homes, most HCT providers have already developed the structures that address critical requirements of MACRA for medical homes.
以患者为中心的医疗之家模式是《医疗保险获得和儿童健康保险计划再授权法案》(MACRA)中定义的高级替代支付模式的基础。以患者为中心的医疗之家是一种医疗保健提供模式,得到了替代支付机制的支持,旨在促进协调的医疗服务,同时以患者为中心并面向人群。这种变革性的护理模式要求将报销从按服务项目付费转变为按人头付费,以支付过去未报销的服务费用,如随着时间的推移进行疾病管理。支付与质量指标挂钩,包括按照预先设定的路径提供护理的比例以及对结果产生影响的程度。一些医疗之家还通过降低整体护理成本提供共享储蓄的机会。最近的一些提案建议将医疗之家模式扩展到有复杂需求的特殊人群,因为初级保健团队可能没有满足其独特需求的设施或必要的专业知识。造血细胞移植(HCT)中心已经提供多学科、协调和高度专业化的护理,是一种成功的护理模式,可能为那些正在创建专业医疗之家模式的人提供宝贵的经验,其已经存在于许多 HCT 中心。HCT 中心之所以能够整合护理服务,是因为其患者需要专科护理,以及商业支付方所偏好的支付方式,包括将移植期间的住院和门诊护理捆绑在一起。商业支付方根据认证状态和比较绩效来确定合格的 HCT 中心,这在一定程度上得益于 2005 年《干细胞治疗和研究法案》强制要求的全国性结果数据库中的中心级比较绩效数据。通过细胞治疗认证基金会实施的自愿认证,促进了中心之间的标准化。支付方在此基础上建立了这些社区制定的计划,并将公开的结果和项目认证作为纳入专科护理网络和合同的必要标准。尽管 HCT 中心尚未被描述为医疗之家,但大多数 HCT 提供者已经建立了满足 MACRA 对医疗之家的关键要求的结构。